Articles tagged with Glioblastomas
A new study shows targeted delivery of energy-disrupting gene therapy using nanoparticles shrinks glioblastoma brain tumors and aggressive breast cancer tumors in mice. The technology, mLumiOpto, induces light-activated electrical currents inside cells to disrupt mitochondria, leading to programmed cell death and DNA damage.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers used lab-grown organoids from glioblastoma tumors to model patient response to CAR T cell therapy. The organoids accurately reflected the treatment's effect on actual tumors, providing a promising tool for personalized medicine.
Scientists have created a living cell therapy that can navigate to specific organs using a
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
Scientists at WashU Medicine have successfully forced glioblastoma cells to display immune system targets, potentially making them vulnerable to immunotherapies. The strategy involves a combination of two FDA-approved epigenetic therapy drugs that induce the production of unusual proteins called neoantigens.
Glioblastoma is a deadly form of brain cancer affecting 500 Swedes annually. Researchers have identified 'foam cells' that aid tumour growth by releasing signal substances and promoting blood vessel formation.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
A recent clinical trial analysis found that patients with truly unmethylated MGMT promoter do not benefit from temozolomide treatment, challenging current treatment protocols. This study aims to transform the treatment landscape for older adults glioblastoma patients by identifying biomarkers for more personalized therapies.
A new study by Sylvester Comprehensive Cancer Center researchers shows that daily MRI imaging paired with radiation can monitor tumor changes in real-time. The technology has the potential to signal early warning signs of tumor growth, allowing for faster and more targeted treatment adaptations.
Researchers created an artificial blood vessel model using 3D bioprinting to test new therapies for glioblastoma. This device enables the creation of personalized disease models, potentially improving patient survival rates.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers have uncovered a critical mechanism by which mutant p53 protein converts other proteins into cancer-promoting agents, driving tumor growth. Heparin, a widely used anticoagulant, can inhibit the formation of these harmful aggregates, providing a potential therapeutic approach.
Researchers have successfully visualized and tracked specific cells in deep brain tissue, including along the corpus callosum's nerve fibre highway. This advancement could potentially lead to better diagnostic tools for glioblastoma, a deadly brain cancer.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
A novel, automated device has been developed to diagnose glioblastoma in under an hour using a biochip that detects biomarkers. The device requires only 100 microliters of blood and costs less than $2 to manufacture.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Scientists found islands of highly potent immune cells in the bone marrow close to glioblastoma tumors, which play a central role in defending against cancer. This discovery may lead to innovative therapies and could improve patients' chances of survival.
Scientists used AI to identify genes that can convert brain cancer cells into immune cells, increasing survival chances by up to 75% in mouse models. The approach bypasses the blood-brain barrier, offering new hope for aggressive cancers.
Scientists discovered that Tumour Treating Fields (TTFs) improve Natural Killer cell killing by increasing degranulation, a sign of better cell function. The findings offer promising implications for treating glioblastoma and other cancers.
Researchers at NYU Abu Dhabi have discovered that the tumor suppressor protein Par-4 can cause a unique type of cell death called ferroptosis in human glioblastoma cells, while sparing healthy cells. This new understanding has the potential to inform the development of novel treatments for various hard-to-treat cancers and neurodegener...
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
Researchers found that a 10-nanometer-sized nanoruler achieves the highest brain tumor accumulation, outperforming larger sizes. This discovery offers guidance for designing future brain tumor nanomedicines.
Pre-clinical trials show that targeted alpha radiation therapy can increase survival rates by up to 36.4% and has minimal adverse effects for patients. Researchers hope this new approach could improve current average survival rates beyond 18 months.
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
Adding anlotinib to the standard STUPP regimen for newly diagnosed glioblastoma patients may improve outcomes, with median PFS and OS of 10.9 months and 17.4 months respectively. Further studies are planned to explore this combination therapy's effects on survival and quality of life.
Researchers developed a novel immunotherapy approach using ultrasound to deliver chemotherapy and antibodies to the brain, boosting immune system recognition of glioblastoma cells. The treatment showed promise in improving responses to PD-1 blockade in patients with advanced brain tumors.
Researchers at Dana-Farber Cancer Institute have reported encouraging results from three separate studies on treatments for central nervous system lymphoma, breast cancer, and glioblastoma. CAR T-cell therapy showed a 94% overall response rate in patients with CNS lymphoma, while an antibody-drug conjugate plus checkpoint inhibitor imp...
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
A team from Korea University College of Medicine has discovered the evolutionary process of glioblastoma recurrence through proteogenomic analysis, providing potential therapeutic avenues. They found that recurrent tumors undergo neuronal transition and BRAF protein kinase activation, leading to resistance to standard treatments.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
Glioblastoma suppresses immune system by inducing pro-tumor macrophages via glucose-based epigenetic modification, allowing tumor growth. Targeting PERK enzyme may be a viable strategy to fight deadly brain cancer.
Glioblastoma cancer cells change their appearance and behavior to evade T-cell attack, rendering immunotherapy ineffective. Researchers found that these 'plastic' cells can also exhaust T-cells, making glioblastoma resistant to treatment.
A team of Purdue researchers has developed a novel immunotherapy to combat glioblastoma, a type of brain tumor with limited treatment options. The treatment uses genetically engineered stem cell-derived natural killer cells that can target and eliminate tumors without the need for blood sourcing.
A phase I trial demonstrated AZD1390's manageable safety profile and preliminary efficacy in recurrent and newly diagnosed glioblastoma patients. The study showed improved overall survival, with a median of 12.7 months in patients who received higher doses of AZD1390.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
Researchers at Mass General Cancer Center have achieved dramatic tumor regression in glioblastoma patients after receiving next generation CAR-T therapy. The treatment, known as INCIPIENT, combines two forms of therapy to target mixed cell populations within tumors.
Early trial results from six patients with recurrent glioblastoma show reduced tumor sizes after administering dual-target CAR T cells targeting EGFR and IL13Rα2 intrathecally. This 'dual-target' approach may outsmart the defense systems of GBM, leading to more effective therapies.
Researchers have developed a nanosurgical tool that enables them to study individual living cancer cells in real-time, allowing for vital understanding of how they react to treatment and change over time. This breakthrough could lead to more effective cancer medication, particularly for glioblastoma, the deadliest form of brain tumour.
A new model of glioblastoma's key feature, oncostreams, could help scientists understand how to develop new treatments for this aggressive brain cancer. The model, developed by a team at the University of Michigan, identifies a potential inhibitor that appears to dismantle oncostreams, leading to better survival in mouse models.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
Researchers at the University of Sussex discovered a protein called PANK4 that blocks glioblastoma cancer cells from responding to chemotherapy. Removing the protein leads to improved treatment outcomes and increased life expectancy for patients, with potential for developing a new drug targeting this obstacle.
Researchers at Michigan State University have found a potential breakthrough in treating glioblastoma by targeting an acid sensor on cancer cell membranes. The compound OGM showed remarkable ability to kill glioblastoma cells while leaving normal cells unharmed.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Researchers from UPV propose using rCBV as a predictive marker to identify patients with moderately vascularized tumors who benefit most from bevacizumab treatment. This approach enhances treatment efficacy and improves clinical outcomes.
Researchers identified gartisertib as a potent ATR inhibitor that enhances cell death in patient-derived glioblastoma cell lines. The study also showed synergy between gartisertib and TMZ+RT treatment, with higher sensitivity to gartisertib observed in MGMT promoter unmethylated cells.
Researchers developed a new imaging technique to visualize the tumor microenvironment of glioblastoma, revealing insights into its pathology. The technique uses PET imaging with Carbon-11 acetate, tracking reactive astrocytes and distinguishing them from tumor cells.
Researchers at the University of Miami Miller School of Medicine have discovered that glioblastoma cells can mimic healthy neurons, evading drugs and immune systems. They identified key enzymes and protein modifications, including BRAF, which shows promise as a potential therapy target.
Researchers at the University of Rochester Medical Center find that microglia can trigger cognitive deficits after radiation exposure, potentially targeting them for therapy development. Mice studies showed that blocking a specific pathway in microglia prevented cognitive decline, offering hope for improving patients' quality of life.
Researchers uncover intricate interplay between enhancers and silencers influenced by DNA methylation, providing crucial insights into dynamic gene control. High-resolution mapping reveals how genes are controlled and modified, paving the way for precision medicine tailored to individual patients.
Researchers at Gladstone Institutes used CRISPR to destroy glioblastoma cells in an approach that could be applied to other highly mutated cancers. The technique, dubbed "cancer shredding," targets and rapidly eliminates tumor cells while sparing healthy ones.
Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.
Researchers developed a novel method using extracellular vesicles to deliver mRNA for cancer therapy, overcoming challenges of accurate targeting and production. The approach shows promise for treating hard-to-treat tumor types by reversing immunosuppressive environments and making tumors detectable to the immune system.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
Researchers found that mitochondrial protein CHCHD2 is associated with increased tumor growth, invasion, and resistance to chemotherapy in glioblastoma patients. CHCHD2 interacts with mutated EGFR to increase sensitivity to cytotoxic drugs, highlighting its potential as a therapeutic target.